ArticleCureus2025
Impact of Implementing an Outpatient Antimicrobial Stewardship Program on Urinary Tract Infection Management in a Private Hospital in Costa Rica.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntimicrobial stewardship programs (AMS) improve antibiotic use in both hospital and outpatient (OP) settings. While AMS initiatives in Latin America have focused mainly on inpatient care, OP-specific interventions remain limited. Hospital Clínica Bíblica (HCB) had an AMS program for hospital settings but lacked structured OP activities.
objectivesTo evaluate the implementation of an AMS-OP in a private hospital in Costa Rica, its impact on antibiotic prescribing patterns for urinary tract infections (UTIs), and its feasibility for broader application in the Latin American context.
methodsA retrospective observational study with a pre- and post-intervention design was conducted. The analysis compared OP antibiotic prescribing for UTIs during the pre-AMS-OP period (July 2021-March 2022) and the post-AMS-OP period (July-December 2022). The AMS-OP was implemented from April to June 2022. Baseline compliance with CDC AMS-OP elements was assessed. A total of 269 OP UTI cases were analyzed, focusing on optimal antibiotic selection, physician adherence to clinical guidelines, and clinical outcomes, including recurrence and relapse.
resultsUTIs accounted for 163 (40.1%) of 407 OP antibiotic prescriptions. Pre-AMS-OP, 255 (62.7%) of the antibiotics prescribed belonged to the WHO Watch category. Post-AMS-OP, CDC compliance increased from 28.6% to 85.7%. Optimal antibiotic selection improved from 143 (53.8%) to 126 (95.2%) cases (p < 0.001). The optimal use of ciprofloxacin and levofloxacin improved by 31.3% (p = 0.028) and 60.0% (p = 0.027), respectively. Nitrofurantoin and fosfomycin use increased, while trimethoprim-sulfamethoxazole (TMP-SMX) and fluoroquinolones decreased. Physician adherence scores rose from 46.2 to 90.0. UTI recurrence decreased to 15 cases (11.9%, p = 0.005), and relapse rates fell to 3.1% (p = 0.07).
conclusionsImplementing AMS-OP based on CDC elements significantly improved antibiotic selection, physician guideline adherence, and clinical outcomes for UTIs in the OP setting. This strategy appears feasible and beneficial for OP care in Latin America.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.